The prevalence and the clinical relevance of anti-Ro52 in Korean patients with primary Sjögren's syndrome.
So far, there was no report on the prevalence and clinical relevance of anti-Ro52 in primary Sjögren's syndrome (pSS) patients in Korea. In this study, we investigated the prevalence and the clinical relevance of anti-Ro52 in Korean patients with pSS. We retrospectively reviewed the medical records of 96 patients with pSS. On the first visit clinical manifestations, laboratory features and autoantibodies were assessed. We divided subjects into 4 groups according to the presence of anti-Ro60 or anti-Ro52 and investigated the association between those autoantibodies and clinical manifestations. Anti-Ro52 (66.7%) was the most frequently detected autoantibody, followed by anti-Ro60 (52.1%) and anti-La (49.0%). Patients with anti-Ro52 had higher frequency of liver and muscle involvements than those without, while anti-Ro60 exhibited negative association with liver involvement. Anti-Ro52 showed significant relative risk for liver involvement (OR = 5.987, P = 0.038, 95% CI = 1.109-32.326), while anti-Ro60 showed inverse relative risk for liver involvement (OR = 0.122, P = 0.003, 95% CI = 0.031-0.479). Anti-Ro52 also showed significant OR for muscle involvement (OR = 9.533, P = 0.044, 95% CI = 1.059-85.793). In conclusion, anti-Ro52 was the most frequently detected autoantibody except ANA in patients with pSS in Korea. Anti-Ro52 was significantly associated with liver and muscle involvements, while anti-Ro60 was inversely associated with liver involvement in Korean patients with pSS.
Department of Rheumatology, Chung-Ang University College of Medicine, 224-1 Heuksuk-dong, Dongjak-gu, 156-755 Seoul, South Korea. drsong@cau.ac.kr
Jung-Soo
JS
Song
Jae Hyuk
JH
Do
Sang-Won
SW
Lee
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000974:Antibodies, Antinuclear / Q000096:biosynthesis / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D056910:Republic of Korea / Q000453:epidemiology; D012189:Retrospective Studies; D012261:Ribonucleoproteins / Q000097:blood / Q000276:immunology*; D016036:Seroepidemiologic Studies; D012859:Sjogren's Syndrome / Q000175:diagnosis* / Q000208:ethnology / Q000276:immunology*; D055815:Young Adult; D000099207:SS-A Antigen
D000974:Antibodies, Antinuclear; D012261:Ribonucleoproteins; D000099207:SS-A Antigen; C035356:SS-A antibodies
Medicine (Baltimore). 2001 Jan;80(1):1-8
11204499
Ann Rheum Dis. 2002 Oct;61(10):929-33
12228166
Arthritis Res Ther. 2006;8(1):R4
16356190
J Clin Pathol. 1968 Sep;21(5):656-60
5697370
Ann Rheum Dis. 2008 Jul;67(7):949-54
17962240
Clin Exp Rheumatol. 1999 Mar-Apr;17(2):205-14
10342047
Arthritis Res Ther. 2007;9(4):R78
17688695
Ann Rheum Dis. 1997 Nov;56(11):667-70
9462169
J Rheumatol. 2008 May;35(5):845-9
18381788
Autoimmun Rev. 2008 Dec;8(2):92-4
18692602
J Transl Med. 2009 Sep 24;7:83
19778440
Ann Rheum Dis. 2002 Jun;61(6):554-8
12006334
Autoimmunity. 2000 Sep;32(2):89-92
11078154
Rheumatology (Oxford). 2009 Aug;48(8):964-7
19531627
Autoimmun Rev. 2009 Jun;8(7):632-7
19393201
Lupus. 2003;12(8):623-9
12945722
Ann Rheum Dis. 2002 Dec;61(12):1090-4
12429541